Dataset Information

Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer

ABSTRACT: Part 1: The primary purpose is to determine the recommended dose of E7070 in combination with capecitabine by dose adjustment. Part 2: The primary purpose is to determine the safety and efficacy of the combination in patients with metastatic CRC resistant to 5-fluorouracil and irinotecan.

DISEASE(S): Colorectal Cancer (crc),Metastatic Colorectal Cancer Resistant To Or Unsuitable For Treatment With 5-fluorouracil And Irinotecan And/or Oxaliplatin,Colorectal Neoplasms

PROVIDER: 2016943 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:Purpose: To determine whether capsaicin (CAP) exacerbates experimental autoimmune uveitis (EAU) and whether this effect is associated with impaired intestinal homeostasis, gut microbiota re-modeling, and altered metabolic profiles. Methods: An EAU mouse model was used to evaluate the dose-dependent effects of CAP on ocular inflammation and intestinal homeostasis. EAU severity was assessed by fundus examination, clinical scoring, and retinal histopathology. Ileal and colonic morphology, colonic ZO-1 and MUC2 expression, and IL-17A levels in the colon and spleen were evaluated using hematox-ylin and eosin staining, immunofluorescence, and enzyme-linked immunosorbent assays. 16S rRNA gene sequencing, untargeted fecal metabolomics, and colonic RNA sequencing were performed to characterize CAP-associated changes in the gut microbiota, metabolome, and transcriptome. Kynurenic acid (KYNA) was subsequently administered to determine whether supplementation attenuated CAP-induced exacerbation of EAU and intestinal barrier injury. Results: CAP exacerbated EAU in a dose-dependent manner. At 80 mg/kg, CAP aggravated retinal inflammation and tissue injury, increased clinical and histopathologic scores, and elevated IL-17A levels in the colon and spleen. High-dose CAP was also associated with ileal archi-tectural abnormalities, reduced colonic mucosal thickness, and decreased colonic ZO-1 and MUC2 expression. 16S rRNA gene sequencing revealed alterations in gut microbial diversity and community structure. CAP-associated differential metabolites were enriched in the tryp-tophan metabolism pathway, and fecal KYNA levels were significantly reduced. Colonic RNA sequencing showed enrichment of the IL-17 signaling pathway, upregulation of Il17a, Il17f, and Rorc, and altered expression of genes involved in tryptophan metabolism. KYNA supplementation reduced clinical and histopathologic scores, decreased IL-17A levels in the colon and spleen, and partially restored colonic ZO-1 and MUC2 expression. Conclusion: Under these experimental conditions, high-dose CAP exacerbated EAU and was associat-ed with intestinal barrier disruption, gut microbiota remodeling, altered tryptophan metabo-lism, and enhanced IL-17-related inflammation. The partial attenuation observed after KYNA supplementation supports further investigation of KYNA as a candidate metabolic factor in high-dose CAP-treated EAU mice.

Dataset Information

Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets